Rasburicase: future directions in tumor lysis management
Authors:
- Mitchell S CairoMCMitchell S Cairo
- 7 September 2008
- journal article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 8 (10) , 1595-1604
Abstract
Acute tumor lysis syndrome (TLS) is an oncologic emergency resulting in several metabolic derangements. Hyperuricemia and its associated complications are the most frequent manifestations of TLS. Crucial to the management is the prompt initiation of a hypouricemic agent such as rasburicase. An established dose of 0.2 mg/kg of rasburicase is effective at decreasing uric acid levels significantly in 4 h of administration and to undetectable levels in 48 h of initiation. The mean uric acid AUC is significantly lower for patients treated with rasburicase when compared to those receiving allopurinol. Rasburicase has demonstrated excellent tolerability and is potentially cost-effective in patients at high risk for TLS. Rasburicase is a safe and effective hypouricemic agent for both adults and children at high risk for TLS and for this reason should be considered the uricolytic agent of choice in these patients.Keywords
This publication has 24 references indexed in Scilit:
- Tumor lysis syndrome: current perspectiveHaematologica, 2008
- TUMOR LYSIS SYNDROME IN CHILDREN WITH NON-HODGKIN LYMPHOMAPediatric Hematology and Oncology, 2006
- Pitfalls in predicting tumor lysis syndromeLeukemia & Lymphoma, 2006
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) StudyJournal of Clinical Oncology, 2003
- Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancerCancer, 2003
- Tumor lysis syndromeSeminars in Hematology, 2001
- Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphomaThe American Journal of Medicine, 1993
- Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutationsGene, 1991
- Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemiaThe Journal of Pediatrics, 1982